ArticlePLoS neglected tropical diseases2014
Where the road ends, yaws begins? The cost-effectiveness of eradication versus more roads.
Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Integrated mass drug administration for yaws eradication: evidence from a comparative observational study in Papua New Guinea and a systematic review with network meta-analysis.BMJ global health · 2026Pooled it
- Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication.The New England journal of medicine · 2022Trial
- Geographical disparities and programmatic determinants of hydrocele surgery and lymphoedema management coverage for lymphatic filariasis in the Democratic Republic of the Congo, 2018-2024: A national analysis of routine programme data.PLoS neglected tropical diseases · 2026Article
- Article
- Seroprevalence and geospatial epidemiology of yaws: Evidence from Ghana.PLoS neglected tropical diseases · 2025Article
- Stigma, psychosocial and economic effects of yaws in the Philippines: an exploratory, qualitative study.Tropical medicine and health · 2022Article
- LAMP4yaws:BMJ open · 2022Article
- Article
- Epidemiologic and Genomic Reidentification of Yaws, Liberia.Emerging infectious diseases · 2021Article
- Modeling Treatment Strategies to Inform Yaws Eradication.Emerging infectious diseases · 2020Article
- Insights from quantitative and mathematical modelling on the proposed 2030 goals for Yaws.Gates open research · 2019Article
- Prioritizing surveillance activities for certification of yaws eradication based on a review and model of historical case reporting.PLoS neglected tropical diseases · 2018Review
- Gene target selection for loop-mediated isothermal amplification for rapid discrimination of Treponema pallidum subspecies.PLoS neglected tropical diseases · 2018Article
- Targeted Treatment of Yaws With Household Contact Tracing: How Much Do We Miss?American journal of epidemiology · 2018Article
- The cost and cost-effectiveness of rapid testing strategies for yaws diagnosis and surveillance.PLoS neglected tropical diseases · 2017Article
- Mathematical Modeling of Programmatic Requirements for Yaws Eradication.Emerging infectious diseases · 2017Article
- Benchmarking the Cost per Person of Mass Treatment for Selected Neglected Tropical Diseases: An Approach Based on Literature Review and Meta-regression with Web-Based Software Application.PLoS neglected tropical diseases · 2016Review
- Yaws: towards the WHO eradication target.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2016Article
- Challenges and key research questions for yaws eradication.The Lancet. Infectious diseases · 2015Review
- Yaws.British medical bulletin · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionA disabling and disfiguring disease that "begins where the road ends", yaws is targeted by WHO for eradication by the year 2020. The global campaign is not yet financed. To evaluate yaws eradication within the context of the post-2015 development agenda, we perform a somewhat allegorical cost-effectiveness analysis of eradication, comparing it to a counterfactual in which we simply wait for more roads (the end of poverty).
methodsWe use evidence from four yaws eradication pilot sites and other mass treatment campaigns to set benchmarks for the cost of eradication in 12 known endemic countries. We construct a compartmental model of long-term health effects to 2050. Conservatively, we attribute zero cost to the counterfactual and allow for gradual exit of the susceptible (at risk) population by road (poverty reduction). We report mean, 5th and 95th centile estimates to reflect uncertainty about costs and effects.
resultsOur benchmark for the economic cost of yaws eradication is uncertain but not high -US$ 362 (75-1073) million in 12 countries. Eradication would cost US$ 26 (4.2-78) for each year of life lived without disability or disfigurement due to yaws, or US$ 324 (47-936) per disability-adjusted life year (DALY). Excluding drugs, existing staff and assets, the financial cost benchmark is US$ 213 (74-522) million. The real cost of waiting for more roads (poverty reduction) would be 13 (7.3-20) million years of life affected by early-stage yaws and 2.3 (1.1-4.2) million years of life affected by late-stage yaws. DISCUSSION: Endemic countries need financing to begin implementing and adapting global strategy to local conditions. Donations of drugs and diagnostics could reduce cost to the public sector and catalyze financing. Resources may be harnessed from the extractive industries. Yaws eradication should be seen as complementary to universal health coverage and shared prosperity on the post-2015 development agenda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.